Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

36.44
-1.1800-3.14%
Post-market: 36.34-0.1000-0.27%19:55 EDT
Volume:3.14M
Turnover:115.07M
Market Cap:42.45B
PE:60.73
High:37.42
Open:37.37
Low:36.37
Close:37.62
52wk High:38.37
52wk Low:17.94
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.70
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.48
PE(LYR):30.12

Loading ...

Teva to acquire Emalex Biosciences for $700M at closing

TIPRANKS
·
Apr 29

Notable companies reporting before tomorrow’s open

TIPRANKS
·
Apr 29

Teva put volume heavy and directionally bearish

TIPRANKS
·
Apr 29

Teva’s Home Ground Schizophrenia Push And What It Could Mean For Investors

Simply Wall St.
·
Apr 28

Teva Pharmaceutical Industries Ltd expected to post earnings of 46 cents a share - Earnings Preview

Reuters
·
Apr 27

Earning Preview: Teva Pharmaceutical this quarter’s revenue is expected to decrease by 4.49%, and institutional views are bullish

Earnings Agent
·
Apr 23

Teva put volume heavy and directionally bearish

TIPRANKS
·
Apr 21

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After The Home Ground Schizophrenia Platform Launch

Simply Wall St.
·
Apr 19

US appeals court revives Teva lawsuit against Eli Lilly over migraine drug

Reuters
·
Apr 16

Does Biosimilar Wins in Osteoporosis and Allergy Care Change The Bull Case For Teva (TEVA)?

Simply Wall St.
·
Apr 13

Teva Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Apr 10

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

MT Newswires Live
·
Apr 09

BofA Adjusts Price Target on Teva Pharmaceutical Industries to $42 From $38, Maintains Buy Rating

MT Newswires Live
·
Apr 09

How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones

Simply Wall St.
·
Apr 04

Teva’s New Biosimilars Test Growth Plan And Earnings Reshaping Potential

Simply Wall St.
·
Mar 31

Teva call volume above normal and directionally bullish

TIPRANKS
·
Mar 31

Barclays Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 30

How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases

Simply Wall St.
·
Mar 26

Scotiabank Remains a Buy on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 25

Enphase, AST SpaceMobile, AppLovin, ConocoPhillips, Teva Shock

TIPRANKS
·
Mar 21